2022
Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso
Zupko R, Nguyen T, Somé A, Tran T, Gerardin J, Dudas P, Giang D, Tran K, Wesolowski A, Ouédraogo J, Boni M. Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso. PLOS Global Public Health 2022, 2: e0000111. PMID: 36962300, PMCID: PMC10021447, DOI: 10.1371/journal.pgph.0000111.Peer-Reviewed Original ResearchMultiple first-line therapiesFirst-line therapyTreatment failure rateArtemether-lumefantrineFalciparum malariaCombination therapyLong-term effectsEqual long-term outcomesLower treatment failure rateUncomplicated Plasmodium falciparum malariaMajor global public health concernGlobal public health concernPlasmodium falciparum malariaP. falciparum malariaLong-term outcomesArtemisinin combination therapyP. falciparum transmissionPublic health concernMalaria settingsTreatment failureFailure rateHigh burdenTreatment efficacyACT useDrug resistance
2021
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
Tindana P, de Haan F, Mokuolu O, Guissou R, Bolarinwa O, Ouedraogo J, Tou F, Boon W, Moors E, Dondorp A, Dhorda M, Amaratunga C, Cheah P. Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol. Wellcome Open Research 2021, 6: 75. PMID: 34458588, PMCID: PMC8378406, DOI: 10.12688/wellcomeopenres.16065.1.Peer-Reviewed Original ResearchArtemisinin combination therapyCombination therapyQualitative research methodsViews of stakeholdersDepth interviewsPosition issuesMarket-related issuesCommunity membersNational Malaria Control ProgrammeGlobal malaria deathsArtemisinin combination treatmentSoutheast AsiaGroup discussionsNational regulatory authoritiesMalaria control programmesResearch methodsAfricaACT resistanceMalaria deathsMalaria treatmentStudy protocolMalaria prevalenceAntimalarial medicinesCombination treatmentStakeholders
2014
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
Venkatesan M, Gadalla N, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price R, Mårtensson A, Rosenthal P, Dorsey G, Sutherland C, Guérin P, Davis T, Ménard D, Adam I, Ademowo G, Arze C, Baliraine F, Berens-Riha N, Björkman A, Borrmann S, Checchi F, Desai M, Dhorda M, Djimdé A, El-Sayed B, Eshetu T, Eyase F, Falade C, Faucher J, Fröberg G, Grivoyannis A, Hamour S, Houzé S, Johnson J, Kamugisha E, Kariuki S, Kiechel J, Kironde F, Kofoed P, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya S, Nzila A, Oguike M, Otienoburu S, Ogutu B, Ouédraogo J, Piola P, Rombo L, Schramm B, Somé A, Thwing J, Ursing J, Wong R, Zeynudin A, Zongo I, Plowe C, Sibley C, Asaq Molecular Marker Study Group. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal Of Tropical Medicine And Hygiene 2014, 91: 833-843. PMID: 25048375, PMCID: PMC4183414, DOI: 10.4269/ajtmh.14-0031.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAmodiaquineAntimalarialsArtemetherArtemisininsChildChild, PreschoolChloroquineDatasets as TopicDrug CombinationsDrug ResistanceDrug Therapy, CombinationEthanolaminesFluorenesGenetic MarkersGenotypeHumansInfantKaplan-Meier EstimateLumefantrineMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, GeneticProtozoan ProteinsRisk FactorsConceptsArtemether-lumefantrineP. falciparum multidrug resistance 1 genePlasmodium falciparum chloroquine resistance transporterPfmdr1 copy numberArtemisinin combination therapyIndividual patient dataChloroquine resistance transporterMultidrug resistance 1 geneWorldWide Antimalarial Resistance NetworkParasitologic cureCombination therapyParasite polymorphismsPartner drugsTherapeutic responseClinical trialsRelevant outcomesArtemisinin componentPatient dataResistance transporterStandardized methodPolymorphismPatientsPfmdr1PfcrtAmodiaquine